Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Treponema pallidum macrolide resistance in BC

Muhammad G. Morshed and Hugh D. Jones
CMAJ January 31, 2006 174 (3) 349; DOI: https://doi.org/10.1503/cmaj.1050256
Muhammad G. Morshed
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugh D. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Since mid-1997 British Columbia has experienced an outbreak of syphilis, initially in heterosexuals and more recently among men who have sex with men (MSM). Starting in 1999, primarily in patients presenting to the sexually transmitted diseases clinic at the BC Centre for Disease Control (BCCDC), moist lesions of primary and secondary syphilis were swabbed for polymerase chain reaction (PCR) testing for Treponema pallidum. The PCR method used was polA gene amplification using a CDC protocol.1

When the question of azithromycin resistance arose in 2004, specimens were examined retrospectively for the mutation in the T. pallidum 23sRNA gene in collaboration with investigators from the University of Washington.2

From 2000–2003, 1 of 47 positive PCRs showed resistance in a travel- acquired heterosexual case. In 2004, 4 of 9 positive PCRs showed the resistant gene, all in MSM.

The 23sRNA gene correlated with clinical resistance to azithromycin in Dublin and San Francisco.2

All of the BC patients received penicillin G benzathine or doxycycline; therefore, treatment failure with azithromycin was not tested.

Treatment of choice in BC for early syphilis is one dose of penicillin G benzathine (2.4 MU intramuscularly). Oral doxycycline therapy (100 mg twice daily for 2 weeks) is a second-line treatment, with oral azithromycin therapy (one 2-g dose) as a third-line treatment, especially in noncompliant patients who refuse injections. This sequence is in compliance with the Canadian and US STD treatment guidelines.3,4

In a recent study in Africa, a 2-g oral dose of azithromycin was as effective as a 2.4-MU intramuscular dose of penicillin G benzathine.5 However, in developed countries, because of resistance trends, azithromycin should be reserved as a third-line treatment for early syphilis, and patients thus treated should be followed closely, both serologically and clinically.

Footnotes

  • Competing interests: None declared.

REFERENCES

  1. 1.↵
    Hsi L, Rodes B, Chen CY, et al. New tests for syphilis: rational design of a PCR method for detection of Treponema pallidum in clinical specimens using unique regions of the DNA polymerase I gene. J Clin Microbiol 2001;39:1941-6.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Lukehart SA, Godornes C, Molini MS, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004;351:154-8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Health Canada. Canadian STD Guidelines. 1998.
  4. 4.↵
    US Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51(RR-6):1-78.
    OpenUrlPubMed
  5. 5.↵
    Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353:1236-44.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (3)
CMAJ
Vol. 174, Issue 3
31 Jan 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treponema pallidum macrolide resistance in BC
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treponema pallidum macrolide resistance in BC
Muhammad G. Morshed, Hugh D. Jones
CMAJ Jan 2006, 174 (3) 349; DOI: 10.1503/cmaj.1050256

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Treponema pallidum macrolide resistance in BC
Muhammad G. Morshed, Hugh D. Jones
CMAJ Jan 2006, 174 (3) 349; DOI: 10.1503/cmaj.1050256
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Macrolide Resistance in the Syphilis Spirochete, Treponema pallidum ssp. pallidum: Can We Also Expect Macrolide-Resistant Yaws Strains?
  • Azithromycin-Resistant Syphilis-Causing Strains in Sydney, Australia: Prevalence and Risk Factors
  • Detection of the A2058G and A2059G 23S rRNA Gene Point Mutations Associated with Azithromycin Resistance in Treponema pallidum by Use of a TaqMan Real-Time Multiplex PCR Assay
  • Evaluation of Macrolide Resistance and Enhanced Molecular Typing of Treponema pallidum in Patients with Syphilis in Taiwan: a Prospective Multicenter Study
  • Global Challenge of Antibiotic-Resistant Treponema pallidum
  • Molecular Characterization of Syphilis in Patients in Canada: Azithromycin Resistance and Detection of Treponema pallidum DNA in Whole-Blood Samples versus Ulcerative Swabs
  • Canadian guidelines on sexually transmitted infections, 2006
  • Google Scholar

More in this TOC Section

  • An expanded role for blood donor emerging pathogens surveillance
  • Beyond wastewater surveillance: refining environmental pathogen detection in the built environment
  • Observational evidence in support of screening for depression during pregnancy and the postpartum period
Show more Letters

Similar Articles

Collections

  • Topics
    • Drugs: antimicrobials
    • Sexually transmitted infections

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire